Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -296.12% | -98.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -296.12% | -98.84% | |||
| Cost of Revenue | -0.82% | -9.96% | |||
| Gross Profit | -9.55% | -152.99% | |||
| SG&A Expenses | 8.00% | -6.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.40% | -8.77% | |||
| Operating Income | -8.97% | -227.75% | |||
| Income Before Tax | 58.79% | -274.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 57.60% | -274.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 57.60% | -274.78% | |||
| EBIT | -8.97% | -227.75% | |||
| EBITDA | -7.96% | -223.91% | |||
| EPS Basic | 64.19% | -295.64% | |||
| Normalized Basic EPS | -61.69% | -162.40% | |||
| EPS Diluted | 63.11% | -308.57% | |||
| Normalized Diluted EPS | -61.69% | -166.40% | |||
| Average Basic Shares Outstanding | 18.40% | 28.39% | |||
| Average Diluted Shares Outstanding | 18.40% | 20.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||